Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jay Fishman

Infectious Disease Boston, MA Medical Doctor

NPI 1912988106 CMS profile 1072803

55 Fruit St, Grj 5 Infectious Disease Associates, Boston, MA 02114

Open in the dashboard

General payments

$44,123

17 records reported · program years 2019–2025

Research payments

$2,275

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jay Fishman of Boston, MA is reported in the CMS Open Payments database as having received $44,123 across 17 general payments and $2,275 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Infectious Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,275 1
2025 Research $2,275 1
2024 General $1,300 1
2023 General $11,524 4
2021 General $9,090 3
2020 General $473 3
2019 General $19,461 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jay Fishman
  • Infectious Disease median
  • Middle half of Infectious Disease
  • National median

In program year 2025, general payments to Jay Fishman were reported at $2,275. Among 3,905 Infectious Disease profiles paid that year, the median was $188 and the middle half received between $57 and $766.

Show as a table
Year Jay Fishman Infectious Disease median Middle half National median
2019 $19,461 $190 $60–$862 $163
2020 $473 $124 $32–$606 $114
2021 $9,090 $148 $38–$905 $132
2022 $0 $166 $50–$834 $149
2023 $11,524 $171 $57–$787 $160
2024 $1,300 $176 $52–$752 $164
2025 $2,275 $188 $57–$766 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Roche Diagnostics International Ltd $13,953 3 payments
  2. Kamada Ltd. $9,291 2 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $8,775 1 payment
  4. Chiesi USA, Inc. $5,508 2 payments
  5. Vertex Pharmaceuticals Incorporated $3,575 2 payments
  6. Abbott Laboratories $2,125 1 payment
  7. Astellas Pharma US Inc $788 5 payments
  8. Melinta Therapeutics, Inc. $108 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $35,054 13 payments
  2. Travel and Lodging $8,961 3 payments
  3. Food and Beverage $108 1 payment
Products named General payments · program years 2019–2025
  1. RDI Research $13,953 3 payments
  2. CYTOGAM $9,291 2 payments
  3. Alinity m $2,125 1 payment
  4. CRESEMBA $788 5 payments
  5. Rezzayo $108 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. United Therapeutics Corporation $2,275 1 payment

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$1,997

Medicare's payments for the services billed

Medicare patients

11

Average age 59

Services billed

24

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Cancer 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

18 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Infectious Disease in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record